CVX vs LLY: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Chevron Corporation · Energy
$188.52
-23.1% upside to fair value
Grade D
VS
Eli Lilly and Company · Healthcare
$939.47
+71.1% upside to fair value
High Conviction
Grade A
QuantHub Verdict
LLY has more upside to fair value
(+71.1%).
CVX trades at a lower forward P/E
(22.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
LLY |
| Current Price |
$188.52 |
$939.47 |
| Fair Value Estimate |
$145.00 |
$1,607.00 |
| Upside to Fair Value |
-23.1%
|
+71.1%
|
| Market Cap |
$376.9B |
$887.6B |
| Forward P/E |
22.9x
|
27.4x
|
| EV / EBITDA |
7.8x
|
35.8x
|
| Price / Sales |
1.5x
|
14.8x
|
| Price / FCF |
17.0x
|
107.6x
|
| Revenue Growth YoY |
-4.6%
|
+44.7%
|
| Gross Margin |
30.4%
|
83.8%
|
| Operating Margin |
9.0%
|
45.6%
|
| Return on Equity |
6.6%
|
77.8%
|
| Dividend Yield |
4.52% |
0.56% |
| FCF Yield |
5.89%
|
0.93%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Chevron Corporation is a leading integrated oil and gas major with global upstream and downstream operations, a fortress balance sheet, and a shareholder-friendly capital return program. Under CEO Mike Wirth, the company has prioritized disciplined capital allocation, returning over $27 billion to shareholders in 2024 alone through buybacks and dividends, while maintaining a 38-year streak of con…
Eli Lilly remains the dominant GLP-1 franchise holder with Mounjaro and Zepbound generating $36.5B combined in 2025 on 45% total revenue growth to $65.2B. The company guided $80-83B for 2026, well above prior Street consensus, and launched Foundayo (oral GLP-1, FDA approved April 2026) with $1.5B pre-built inventory. At $939 the stock trades at 14.8x P/S, right at its 5-year median, and 27.4x for…
Accumulation Zones
| Metric |
CVX |
LLY |
| Zone Low |
$108.75 |
$1,205.00 |
| Zone High |
$123.25 |
$1,366.00 |
| In Buy Zone? |
No
|
Yes
|